NCT02600598View on ClinicalTrials.gov

Biological Effects of LEO 43204 in Actinic Keratosis

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

December 27, 2016

Study Completion Date

January 16, 2017

Conditions

Actinic Keratosis

Interventions

DRUG

LEO 43204 Gel, 0.037%

DRUG

LEO 43204 Gel, 0.037%

Trial Locations (2)

11787

Long Island Skin Cancer and Dermatology Surgery, Smithtown

02169

Beacon Clinical Research, LLC, Quincy

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LEO Pharma

INDUSTRY